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Abstract
Background: Over the past two decades, the APOE gene and its polymorphisms have been among the most
studied risk factors of Alzheimer disease (AD) development; yet, there are discrepancies between various studies
regarding their impact. For this reason, the evaluation of the APOE genotype has not been included in the current
European Federation of Neurological Societies guidelines for AD diagnosis and management. This aim of this study
was to add to this discussion by assessing the possible influence of multiple polymorphisms in the promoter region
of the APOE gene and genotypes of its allele E on the risk for dementia.
Methods: We performed a comprehensive analysis of APOE gene polymorphisms, assessed the detected genotypes
and correlated molecular findings with serum apolipoprotein E concentrations. The study comprised 110 patients
with AD and 110 age-matched healthy individuals from the Polish population.
Results: Four polymorphisms of the APOE gene had minor allele frequency exceeding 5 % and were included
in the analysis: −491A/T (rs449647), −427T/C (rs769446), −219T/G (rs405509) in the promoter region and
+113G/C (rs440446) in intron 1. A protective effect of the −219G allele on AD development was observed.
Also, the −491T and −219G alleles were found to be underrepresented in the carriers of the APOE E4 variant.
On the basis of the genotype and linkage disequilibrium studies, a relative score was attributed to given
genotypes with respect to the estimated probability of their protective effects against AD, giving rise to the
‘preventive score’. This ‘preventive score’, based on the total sums of the relative scores, expresses the
protective effect deriving from the synergistic action of individual single-nucleotide polymorphisms. The
‘preventive score’ was identified as an independent predictive factor.
Conclusions: We propose a novel, more complex approach to AD risk assessment based on the additive
effect of multiple polymorphic loci within the APOE promoter region, which on their own may have too weak
an impact to reach the level of significance. This has potentially practical implications, as it may help to
improve the informative potential of APOE testing in a clinical setting. Subsequent studies of the proposed
system in large, multi-ethnic cohorts are necessary for its validation and to assess its potential practical value
for clinical applications.
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Background
In various studies on multiple distinct ethnic groups and
several different data sets performed over the last two
decades, it has been shown that the epsilon 4 (E4 or ε4)
variant of the apolipoprotein E (APOE) gene is associ-
ated with an increased risk for both sporadic and familial
forms of Alzheimer disease (AD). However, it is also
generally acknowledged that the APOE E4 variant alone
is neither indispensable nor sufficient to cause the dis-
ease [1]. Subsequent series of genome-wide association
studies performed with the aim of identifying further
genetic predisposition sites produced contradictive out-
comes [2]. Therefore, in the pursuit of identifying AD
risk factors, additional APOE gene polymorphisms in the
transcriptional regulatory regions of the gene —the −1000
to +400 proximal promoter region in particular—were in-
vestigated [1]. Three single-nucleotide polymorphisms
(SNPs) were identified as the most promising: −491A/T
(rs449647), −427T/C (rs769446) and −219T/G (rs405509)
[3]. Of these, rs449647 AA and rs405509 TT genotypes
were most commonly associated with AD. A number of
validation studies, including a large meta-analysis consist-
ing of 1732 patients with dementia and 1926 healthy con-
trol subjects [4], performed with individuals from various
ethnic groups supported this association. The rs449647
polymorphism was shown to affect constitutional APOE
transcriptional level in vitro [5], with its A allele found to
increase APOE promoter activity and to confer an in-
creased risk of AD independently of APOE E4. Alleles C
and G of rs769446 and rs405509 polymorphisms, respect-
ively, were also shown to increase APOE promoter activity
[6, 7]. Further in silico studies provided additional evi-
dence that these promoter polymorphisms are functional
[1]. Interestingly, some studies suggested the role of
rs405509 polymorphism to be age-dependent, with a more
pronounced effect in the older population, both in the
context of normal aging [8] and in the development of de-
mentia [4, 9]. However, not all studies reproduced the re-
ported associations and/or showed rs449647, rs769446
and rs405509 polymorphisms to be independent of E4 sta-
tus [1, 9, 10]. In an attempt to clarify such discrepancies,
our aim in this study was to assess possible associations
between polymorphisms in the promoter region of the
APOE gene and genotypes of its allele E, and the risk for
dementia. We also aimed to assess associations of these
polymorphisms with levels of the APOE protein in the
serum. An additional aim was to assess the existence of
the linkage (haplotype analysis) between APOE gene poly-
morphisms and dementia syndrome.
Methods
Study group
Our study included 110 patients with confirmed AD re-
cruited from psychiatric hospitals and outpatient clinics
by specialists in geriatric psychiatry. The diagnosis of AD
was made on the basis of medical interviews, clinical symp-
toms and appropriate imaging examinations and clinical
scales. All patients had a magnetic resonance imaging
(MRI), computed tomography or single-photon emission
computed tomography examination done and were tested
on clinical scales and tests including the Hachinski
Ischemic Scale, the Geriatric Depression Scale, the Mini
Mental State Examination (MMSE) and the Clock Drawing
Test. Relevant tests aimed at eliminating other possible
causes of impairments in cognitive function were per-
formed during the diagnostic process. These included a
complete blood count, a lipidogram and other tests clinic-
ally appropriate for somatic diseases the patients had.
The age-matched control group consisted of adults
(n = 110) with no signs or symptoms of dementia or a
severe somatic disorder. In the whole group, a de-
tailed questionnaire was completed by the physicians
in charge, addressing putative environmental risk fac-
tors and/or the presence of somatic co-morbidities.
All participants were of European origin and homoge-
neous ethnic (Polish) background.
Molecular and biochemical studies
Genomic DNA was extracted from peripheral blood leu-
cocytes using ionic detergent lysis and proteinase K di-
gestion, phenol/chloroform extraction and isopropanol
precipitation according to standard methods. APOE E2/
E3/E4 alleles (rs429358, rs7412) and promoter polymor-
phisms (rs439382, rs1799981, rs1081103, rs72654465,
rs449647, rs1799982, rs769446, rs72654466, rs405509,
rs72654467, rs9282609, rs440446, rs877973, rs769447)
were determined by polymerase chain reaction (PCR)
followed by Sanger sequencing. The following pairs of
primers were used: 5′-TCT TGC TGA GGC TGG AGT
G-3′ and 5′-CAA GGA TCC CAG ACT TGT CC-3′,
5′-AAG ACC TCT ATG CCC CAC CT-3′ and 5′-CCA
GTC TCG CAT TCC TCA TT-3′, 5′-ACG CGG GCA
CGG CTG TCC AAG GAG-3′ and 5′-CTC GCG GGC
CCC GGC CTG GTA CAC-3′. Bidirectional sequencing
analysis of PCR products was performed using an
Applied Biosystems 3130 Genetic Analyzer and the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA). Sequences were ana-
lysed using Sequencher version 4.10.1 DNA sequencing
software (Gene Codes Corporation, Ann Arbor, MI,
USA). The ApoE level (expressed as milligrams per deci-
litre) was estimated by using the electroimmunodiffusion
method using HYDRAGEL Protein(E) assay (Sebia, Evry
Cedex, France) as described previously [11].
Statistical analyses
Minor allele frequency (MAF) <5 % was the criterion for
exclusion from further statistical analysis. Genotype
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analysis was performed using additive, genotypic and
dominant models; (only significant findings are presented
further in the paper). Frequencies were compared using χ2
tests with continuity corrections or Fisher’s exact test with
Freeman-Halton extension for 2 × 3 and 2 × 4 tables when
applicable. For continuous variables, differences between
groups were evaluated using the Kruskal-Wallis test for
global comparisons and Mann-Whitney U tests for pair-
wise comparisons. Unconditional logistic regression was
used to examine the association between APOE genotypes
and AD. In univariate analyses, the Bonferroni correction
for multiple testing was applied. Background characteris-
tics (age, sex, education level, residence) were incorpo-
rated into the analyses. In the logistic regression analysis,
indicator variables for the sex, education level and resi-
dence were added to the models. All calculations were
performed using STATISTICA 12 software (StatSoft,
Tulsa, OK, USA) data analysis software system.
Results
Clinical and demographic data
No significant differences were noted between patients
and control subjects with respect to age, family history or
the most common factor risk factors associated with de-
mentia: previous episodes of depression, past head trau-
mas, concomitant cardiovascular disorders, diabetes or
thyroid disease. The control group included more females
due to availability of participants via established and ethic-
ally approved recruitment routes (see Table 1). The me-
dian MMSE scores were 20.3 (range 15–25) for the study
group and 30 (range 28–30) for the control group.
Univariable analyses of individual SNPs
The genotyping rate was 100 % in the study and control
groups. Only six polymorphisms were found to have
MAF exceeding 5 % and hence were eligible for statis-
tical evaluation: rs449647, rs769446 and rs405509 in the
promoter region; rs440446 in intron 1; and rs429358
and rs7412 in exon 4. The genotype distribution did not
deviate significantly from the Hardy-Weinberg equilib-
rium. The observed frequencies of each SNP are pre-
sented in Table 2.
For each of the studied SNPs of the promoter/intron 1
region, no correlations between age at disease onset, sex,
family history or somatic co-morbidities were observed.
The presence of allele G of rs405509 conferred a pro-
tective effect against AD (OR 0.52 (95 % CI 0.36–
0.75; p < 0.001). A similar tendency was observed with
respect to allele T of rs449647; however, the correl-
ation did not reach the level of significance (Table 2).
Alleles T, G and C of rs449647, rs405509 and rs440446
SNPs, respectively, were significantly underrepresented in
the carriers of the E4 variant.
ApoE serum levels were significantly lower in patients
with AD (5.7 mg/dl vs. 6.5 mg/dl; p < 0.0001). Of the
studied SNPs, only the rs449647 polymorphism signifi-
cantly correlated with ApoE serum concentration. The
presence of its allele A was associated with lower ApoE
levels. Also, the differences in ApoE levels with respect
to APOE epsilon variants were statistically significant
(p < 0.001). The lowest levels of ApoE were noted
among E4 carriers (3.72 ± 0.8 mg/dl for E4/E4 geno-
type, 5.54 ± 1.2 mg/dl for E3/E4 genotype), while the high-
est values were observed in E2 carriers (7.04 ± 1.36 mg/dl
for E2/E3 genotype, 7.23 ± 0.5 mg/dl for E2/E4 genotype).
Cases with E3/E3 genotype had a mean value of
6.38 ± 1.48 mg/dl. No subject with E2/E2 genotype
was present in either the study or the control group.
Table 2 summarizes the results of univariable analyses.
Haplotype and linkage disequilibrium analyses
Haplotype analysis of the entire APOE gene sequence
(chromosome 19q, 50,100,879–50,104,489; GRCh36.3/
hg18) was performed using Haploview 4.2 software, and
data representative of the four distinct populations with
African, Asian and European ancestry were retrieved
from the HapMap database (http://hapmap.ncbi.nlm.-
nih.gov [accessed May 2011]) [12]. The analysis revealed
five tag SNPs forming no haplotype blocks (Additional
file 1). Subsequently, we evaluated the impact of APOE
genotypes reported previously as predictive of the risk of
AD [13]. In the genotypes comprising the E2 variant, no
statistically significant differences between the study and
control groups were observed. In the genotypes com-
prising at least one E4 variant, the −491AA/−219TT/E4
genotype was shown to increase the risk of AD (OR 5.4,
95 % CI 1.14–25.6; p = 0.02).
Afterwards, the experimental data for Polish population
was analysed for the putative linkage disequilibrium (LD).
Table 1 Clinical and demographic data for patients with
Alzheimer disease and healthy volunteers
Patients Healthy
volunteers
Sex, F:M 51:59 85:25
Age, years 71.2 (9, 48–89) 66.8 (7.5, 55–94)
Age at onset, years 67.9 (8.6, 46–85) N/A
Time from disease onset, years 3.6 (1.9, 1–10) N/A
Education level, n
Higher education/university 25 64
Secondary education of general type 45 40
Secondary education of technical
training type
18 4
Primary school education 22 0
N/A not applicable
Continuous variables are shown as mean (SD, range). There are no statistically
significant differences between groups (p > 0.05) apart from sex distribution
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LD between loci rs449647, rs405509 and rs440446 on one
side, and the APOE exon 4 loci coding for epsilon variants
(distant by 3 kb) on the other, was observed. Of all SNPs
analysed, the strongest LD was observed for rs440446
and rs429358 (Lewontin coefficient D′ 0.956, loga-
rithm of [base 10] odds [LOD] 11.51, r2 = 0.127). The
rs440446 locus was simultaneously linked with pro-
moter SNPs, too, for instance with rs405509 locus
distant by 0.3 kb (Lewontin coefficient D′ 0.925, LOD
32.78, r2 = 0.428).
Multivariable analyses of the analysed risk factors
In the multivariate logistic regression analysis, the initial
testing was performed using six covariates identified in
the aforesaid univariate analyses (−491A/T, −219 T/G,
+113G/C, E4, E2, ApoE level) and the demographic indi-
cator variables for sex, education level and residence.
The initial analysis of all nine plausible factors identified
four covariates: E4, education level, male sex and resi-
dence in large cities as the significant predictors of risk
of AD development. Next, the best subsets search
method was used to verify the optimal set of predictors.
The model likelihood statistics were computed for every
possible predictor subset to identify the best subset.
Eventually, the best model comprising four independent
predictors of AD development was identified. The sig-
nificant factors included two associated with higher risk
(E4 with OR 4.12, 95 % CI 1.55–11.00; male sex with
OR 3.26, 95 % CI 1.46–7.27) and two associated with
lower risk (residence in large cities with OR 0.04,
95 % CI 0.01–0.37; education level with OR 0.23,
95 % CI 0.14–0.40).
‘Preventive score’
The results of simple and multivariable analyses of pro-
moter SNPs along with linkage disequilibrium data were
ultimately used as the foundation for the ‘preventive
score’. Since, on the one hand, none of the studied pro-
moter SNPs was identified as an independent prognostic
factor by logistic regression, and on the other, the pro-
moter SNPs were found in strong linkage disequilibrium,
we decided to test the plausible additive benefit of their
joint analysis. Accordingly, for a given genotype, a rela-
tive score was attributed with respect to its estimated
probability of protective effect against AD (Table 3).
The risk for AD development expressed as the
‘preventive score’ resulting from the total sum of the
relative scores (minimum 0, maximum 4) was found to






Alzheimer disease Presence of E4 isoform Presence of E2 isoform ApoE serum level
rs449647 (AT) 15.0 % 21.8 % Allele T OR 0.63
(95 % CI 0.39–1.01),
p 0.07
Underrepresented in
carriers of allele Ta,b
genotypes AT, TTa,b
Correlates with allele
Ta,c genotypes AT, TTa,c
Lower ApoE levels in
carriers of allele Ad




rs405509 (TG) 39.8 % 55.9 % Allele Ga,c
OR 0.52
(95 % CI 0.36–0.75)
Underrepresented in






rs440446 (CG) 33.5 % 38.6 % n.s. Underrepresented in






rs429358 (TC) 28.9 % 9.1 % Allele Ca,c
OR 4.1
(95 % CI 2.4–6.9)
N/A N/A Lower ApoE levels in
carriers of allele C,a,b
genotypes CT, CCa,c
rs7412 (CT) 3.9 % 6.4 % n.s. N/A N/A Higher ApoE levels in
carriers of allele Td
E4 N/A N/A OR 4.7a,c
(95 % CI 2.5–8.6)
N/A N/A Lower ApoEe levels in
carriers of E4a,c
E2 N/A N/A OR 0.40
(95 % CI 0.15–1.07),
p 0.1
N/A N/A Higher ApoEe levels in
carriers of E2a,b
ApoE apolipoprotein E, AD Alzheimer disease, E epsilon isoform of the apolipoprotein E, MAF minor allele frequency; n.s. not significant, N/A not applicable, OR
odds ratio, CI confidence interval




eDetailed description with respect to all genotypes is provided in the Results section
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be inversely related to its value. The average ‘preventive
score’ in the AD group was 1.08, compared with 1.55 in
the control group (p = 0.0001). ‘Preventive score’ corre-
lated with presence of the E2 allele (Spearman rank cor-
relation 0.40; p < 0.05) and inversely with the E4 allele
(Spearman rank correlation 0.13; p < 0.05). The ‘preventive
score’ correlated significantly with protein ApoE levels
(Spearman rank correlation 0.25; p < 0.05), while such a
correlation was not seen for individual SNPs.
The significance of 'preventive score' was further
tested with multivariate logistic regression, performed in
the same way as described above. The only difference
was the replacement of the −491A/T, −219T/G, +113G/
C and E2 covariates by the ‘preventive score’. The result-
ing best subset consisted of five independent prognostic
factors: two associated with higher risk (E4 with OR
3.96, 95 % CI 1.90–8.26; male sex with OR 3.09, 95 % CI
1.42–6.74) and three associated with lower risk (educa-
tion level with OR 0.25, 95 % CI 0.15–0.41; residence in
large cities with OR 0.04, 95 % CI 0.01–0.38; ‘preventive
score’ with OR 0.62, 95 % CI 0.40–0.96). The additive
benefit of the ‘preventive score’ is roughly half the effect
of E4 in the model.
Additional statistical analyses using the logistic regres-
sion model in the subgroups of patients resulting from
an inclusion/exclusion of the E2 and E4 allele carriers
and in the sub-group homozygous for the E3 allele, have
shown that the ‘preventive score’ allows for further de-
lineation of the eventual risk of AD development in the
subgroup of E4 carriers (for more details, see Additional
file 2).
Discussion
We report a 9.1 % incidence of the APOE E4 variant in
our sample derived from the Polish population, which is
in line with previously published values [14]. Similarly to
previous studies, we were able to show that the presence
of at least one E4 variant confers almost a five times
higher risk of AD development and that this correlation
is gender-dependent [2]. For women, the presence of E4
variant conferred almost an eight times higher risk,
while for men the association was not statistically
significant (data not shown). In contrast to previously
published results, no correlation between the presence
of the E4 variant and the age of AD onset was ob-
served [15]. However, our study group did not include
many individuals diagnosed when they were older
than 80 years of age, as late-onset AD was not a pri-
ority in our study. This might have resulted in the
lack of such a correlation in our data.
Despite the reproducibility of the APOE E4 variant asso-
ciation with AD development, also shown in our study,
the pathomechanism of such a correlation remains largely
unsolved. Hence, an intense search for additional modify-
ing factors, both intragenic and located at other loci of the
genome, has been conducted worldwide. Of these,
two APOE promoter SNPs—rs449647 (−491A/T) and
rs405509 (−219T/G)—were shown to have predictive
value for AD development [1–3, 5, 6, 9, 16–22].
However, not all studies were able to reproduce the
protective effect in their populations, for instance in
French [10], Irish [23], Finnish [24] or Japanese [25].
Hence, the exact role of these SNPs and their interaction
with epsilon variants—in other words, their predictive
character being independent or derivative of epsilon
status—remains a subject of intensive debate.
In the present study, we were able to show a protective
effect of −219G (rs405509) allele in a sample derived from
the Polish population, while the correlation with the
−491T (rs449647) allele did not reach the level of signifi-
cance. This is interesting in light of an MRI study by Chen
et al. [4], who showed an accelerated age-related reduction
of thickness in the left parahippocampal gyrus in −219 TT
carriers and suggested it as the neural substrate under-
lying a faster decline in cognition in individuals with this
genotype. Hence, carrying a G allele might offer protec-
tion against such a process and act protectively in terms
of cognition. The Chen et al. [4] study, as well as a few
others (see, e.g., [9]), showed the effect of this polymorph-
ism to be age-related. As most individuals (95 of 110) in
our study were mostly older than 60 years of age, this ef-
fect might have been more pronounced.
In addition, we observed that both alleles, −219G
and −491T, were significantly underrepresented in the
carriers of the E4 variant. Such characteristics render
the variants plausible candidates for independent risk/
protective factors for AD development. However, the
latter was not confirmed in the multivariable logistic
regression analysis.
The inconsistent findings in previous studies regarding
the presence of LD between promoter polymorphisms
and the APOE epsilon variant coding SNPs were explained
by the suggestion that LD may vary significantly
depending on ethnic background. Here, we have shown
the presence of a significant LD in the coherent group of
Polish patients, being a large ethnic group with a low rate
Table 3 Relative scores for individual APOE promoter single-
nucleotide polymorphism genotypes used for evaluation of the
‘preventive score’ against Alzheimer disease
Genotype Relative score
rs449647: AT heterozygote 1
rs449647: TT homozygote 2
rs405509: TG heterozygote 1
rs405509: GG homozygote 2
Other genotypes 0
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of consanguinity. The analysis of data retrieved from the
HapMap project showed no haplotype blocks within the
APOE gene. However, various differences in LD between
individual SNPs have been observed in all ethnic groups.
Lescai et al. [13] performed a similar, large-scale haplotype
analysis in a group of more than 1000 Italian subjects and
showed the presence of individual LDs but not haplotype
blocks. In their study of the prognostic role of APOE
SNPs on AD risk, the only significant additive effect
has been observed for the rs405509 allele T/E4 haplo-
type present in phase (i.e., ‘in cis’). They did not per-
form a more comprehensive analysis that would
include other in phase SNP loci. In our present study,
we were able to show that the presence of the
−491AA/−219TT/E4 genotype appears to be even
more informative. It has been shown that lower ApoE
levels are associated with a higher risk of developing AD.
As −491A, −219T and E4 alleles have all been shown to
independently decrease APOE gene expression, and hence
ApoE levels [5–7], a haplotype containing all three alleles
might confer a higher risk for AD because of the synergis-
tic action of all three variants. Promoter SNPs confer a
mild but additive effect on APOE expression. We showed
that the ‘preventive score’ correlated significantly with
protein ApoE levels, while this was not the case when in-
dividual SNPs were considered. It is possible that the
SNPs need to be assessed jointly for their impact to reach
significance, which might be one of the possible explana-
tions for discrepancies in the previous reports. The results
of the analysis of the above-tested polymorphisms in the
promoter region of the APOE gene, in addition to increas-
ing knowledge of the allelic variants of the gene, can be
important for determining the risk of the incidence of
dementia.
We believe that one of the most important findings of
this study is the identification of the ‘preventive score’.
Its importance derives from the fact that it takes into ac-
count an additive risk related to the presence of alleles
and genotypes, which on their own may have too weak
an impact to reach the level of significance. This has po-
tentially practical implications, as it may help improve
the informative potential of APOE testing in a clinical
setting. The APOE testing, limited to the evaluation of
the E4 variant, was not found to be sufficiently inform-
ative to be included in the current European Federation
of Neurological Societies guidelines for AD diagnosis
and management [26]. Here, we show that the ‘preventive
score’ has an independent prognostic value, regardless of
E4 status. Moreover, it has been shown to be more in-
formative than serum ApoE levels, the ultimate marker of
gene expression. The latter, owing to the complexity of
protein-protein interactions and the impossibility of their
direct measurement in the tissue of choice (i.e., brain),
appears to be a less preferable parameter.
One important issue is the relationship between the
‘preventive score’ and epsilon variants, namely whether
the ‘preventive score’ is independent of their effect, and
especially the effect of the E2 allele. We attempted to
tackle this issue by performing additional statistical ana-
lyses using the logistic regression model in the sub-
groups of patients resulting from inclusion/exclusion of
the E2 and E4 allele carriers and in the subgroup homo-
zygous for the E3 allele. They have shown that the
‘preventive score’ allows for further delineation of the
eventual risk of AD development in the subgroup of E4
carriers and supports the role of the ‘preventive score’ as
an additional diagnostic tool. However, these results
need to be viewed with caution, as the sizes of the sub-
groups after the removal of the E2 and E4 alleles carriers
were small (for example, only 5 % of patients with AD
and 12 % of control subjects were E2 carriers), and a
well-discriminating distribution of the epsilon alleles was
not possible to obtain; for example, E2 homozygotes
were lacking in both cohorts.
We believe that the utility of the ‘preventive score’ is
an interesting and potentially useful finding; however,
our results need to be replicated to confirm the validity
of the score. Hence, future studies by independent
research groups with larger numbers of patients are
warranted.
Conclusions
We propose the ‘preventive score’ as a new predictive
factor in AD. In contrast to known AD susceptibility
markers, the score does not predispose to AD develop-
ment but allows an estimation of individual risk for the
disease. Nevertheless, further studies with large, multi-
ethnic cohorts are necessary to establish its realistic
utility in clinical settings.
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